JNJ's Icotrokinra Shows Positive Phase 3 Results In Scalp, Genital Psoriasis
9/5 17:19
(RTTNews) - Johnson & Johnson (JNJ) Friday reported positive Phase 3 ICONIC-TOTAL data for Icotrokinra, a once-daily oral peptide that selectively inhibits the IL-23 receptor....